{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:12:51Z","timestamp":1779333171547,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41391-025-01021-3","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:19:45Z","timestamp":1757607585000},"page":"360-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4097-5107","authenticated-orcid":false,"given":"Martin","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grgur","family":"Miri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Galbreath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Fiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Moningi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Orio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.22.01856","volume":"41","author":"JM Michalski","year":"2023","unstructured":"Michalski JM, Winter KA, Prestidge BR, Sanda MG, Amin M, Bice WS, et al. Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG oncology RTOG 0232 randomized clinical trial. J Clin Oncol. 2023;41:4035\u201344.","journal-title":"J Clin Oncol"},{"key":"1021_CR2","doi-asserted-by":"crossref","unstructured":"King MT, Merrick GS, Galbreath RW, Fiano R, Butler WM, Wallner KE, et al. Prospective evaluation of supplemental external beam radiotherapy with palladium-103 prostate brachytherapy: long-term results of the 44\/20\/0 trials. Pract Radiat Oncol. 2025;15:e276-85.","DOI":"10.1016\/j.prro.2024.10.005"},{"key":"1021_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Versiion 2.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"1021_CR4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","volume":"20","author":"MT King","year":"2021","unstructured":"King MT, Keyes M, Frank SJ, Crook JM, Butler WM, Rossi PJ, et al. Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement. Brachytherapy. 2021;20:1114\u201329.","journal-title":"Brachytherapy"},{"key":"1021_CR5","first-page":"78","volume":"6","author":"GS Merrick","year":"2000","unstructured":"Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol. 2000;6:78\u201384.","journal-title":"Tech Urol"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2214\/AJR.19.21836","volume":"214","author":"S Woo","year":"2019","unstructured":"Woo S, Han S, Kim TH, Suh CH, Westphalen AC, Hricak H, et al. Prognostic value of pretreatment MRI in patients with prostate cancer treated with radiation therapy: a systematic review and meta-analysis. Am J Roentgenol. 2019;214:597\u2013604.","journal-title":"Am J Roentgenol"},{"key":"1021_CR7","unstructured":"Rakauskas A, Peters M, Ball D, Kim NH, Ahmed HU, Winkler M, et al. The impact of local staging of prostate cancer determined on MRI or DRE at time of radical prostatectomy on progression-free survival: a Will Rogers phenomenon. Urol Oncol Semin Orig Investig https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1078143922004057."},{"key":"1021_CR8","unstructured":"Baboudjian M, Gondran-Tellier B, Touzani A, Martini A, Diamand R, Roche JB, et al. Magnetic resonance imaging\u2013based t-staging to predict biochemical recurrence after radical prostatectomy: a step towards the iTNM classification. Eur Urol Oncol. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2588931122001699."},{"key":"1021_CR9","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.240041","volume":"313","author":"DD Yang","year":"2024","unstructured":"Yang DD, Lee LK, Tsui JMG, Leeman JE, McClure HM, Sudhyadhom A, et al. AI-derived tumor volume from multiparametric mri and outcomes in localized prostate cancer. Radiology. 2024;313:e240041.","journal-title":"Radiology"},{"key":"1021_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pros.20759","volume":"68","author":"C Gosselaar","year":"2008","unstructured":"Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schr\u00f6der FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate. 2008;68:985\u201393.","journal-title":"Prostate"},{"key":"1021_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.eururo.2019.09.005","volume":"77","author":"G Gandaglia","year":"2020","unstructured":"Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumigui\u00e9 M, et al. The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging\u2013targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. Eur Urol. 2020;77:733\u201341.","journal-title":"Eur Urol"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2630::AID-CNCR20>3.0.CO;2-L","volume":"85","author":"BJ Davis","year":"1999","unstructured":"Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, et al. The radial distance of extraprostatic extension of prostate carcinoma. Cancer. 1999;85:2630\u20137.","journal-title":"Cancer"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0360-3016(99)00405-8","volume":"46","author":"GS Merrick","year":"2000","unstructured":"Merrick GS, Butler WM, Dorsey AT, Lief JH, Benson ML. Seed fixity in the prostate\/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:215\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.brachy.2006.09.003","volume":"6","author":"AY Ho","year":"2007","unstructured":"Ho AY, Burri RJ, Jennings GT, Stone NN, Cesaretti JA, Stock RG. Is seminal vesicle implantation with permanent sources possible? A dose\u2013volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy. 2007;6:38\u201343.","journal-title":"Brachytherapy"},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ijrobp.2021.12.164","volume":"112","author":"S Raman","year":"2022","unstructured":"Raman S, Keyes M, Oh J, Rousseau E, Krauze A, Wilson D, et al. Patterns of prostate cancer recurrence after brachytherapy determined by prostate-specific membrane antigen\u2013positron emission tomography and computed tomography imaging. Int J Radiat Oncol. 2022;112:1126\u201334.","journal-title":"Int J Radiat Oncol"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"WJ Morris","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol. 2017;98:275\u201385.","journal-title":"Int J Radiat Oncol"},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2:e188006.","journal-title":"JAMA Netw Open"},{"key":"1021_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijrobp.2024.09.009","volume":"121","author":"TAC Kennedy","year":"2025","unstructured":"Kennedy TAC, Ong WL, Quon H, Cheung P, Chu W, Chung H, et al. Stereotactic radiation therapy for localized prostate cancer: 10-year outcomes from three prospective trials. Int J Radiat Oncol. 2025;121:325\u201330.","journal-title":"Int J Radiat Oncol"},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/bco2.69","volume":"2","author":"CM Chang","year":"2021","unstructured":"Chang CM, McIntosh AG, Shapiro DD, Davis JW, Ward JF, Gregg JR. Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?. BJUI Compass. 2021;2:188\u201393.","journal-title":"BJUI Compass"},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","volume":"64","author":"ZS Zumsteg","year":"2013","unstructured":"Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64:895\u2013902.","journal-title":"Eur Urol"},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jama.2019.20675","volume":"323","author":"KE Hoffman","year":"2020","unstructured":"Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149\u201363.","journal-title":"JAMA"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","volume":"149","author":"JM Crook","year":"2020","unstructured":"Crook JM, Tang C, Thames H, Blanchard P, Sanders J, Ciezki J, et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol. 2020;149:64\u20139.","journal-title":"Radiother Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01021-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01021-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01021-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:41:55Z","timestamp":1779331315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01021-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01021-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Martin King has received research funding from Palette Life Sciences, Bayer Healthcare, and AstraZeneca, outside of the submitted work. Grgur Miri\u0107 has served as a consultant for Theragenics, outside of the submitted work. Robert Galbreath has received a grant from Theragenics for statistical analysis of the submitted work. Peter Orio has received research funding, consulting fees, and stock for Palette Life Sciences, outside of the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Institutional-board approval has been obtained from the Bethany Ethical Research and Animal Care Committee (reference number S24-16). In addition, all patients signed an IRB-approved informed consent form at the time of treatment, which included consent for their clinical data to be used in future research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}